Overview
The TABAC STOP ORL POUMON study aims to evaluate the factors influencing long-term smoking cessation in patients with head and neck cancer (HNC) or lung cancer undergoing radiotherapy or chemoradiotherapy. This is a single-center observational study, following patients at 1, 6, and 12 months after treatment completion. The primary objective is to determine the proportion of abstinent patients at 6 months, while secondary objectives analyze factors influencing abstinence, smoking trajectories, and reasons for relapse. A total of 100 patients will be included to ensure robust statistical analysis.
Description
The TABAC STOP ORL POUMON study is a prospective, single-center observational study aiming to understand factors influencing long-term smoking cessation in patients treated for head and neck or lung cancer. Tobacco is a leading cause of death and disease, particularly in areas like Hauts-de-France with high smoking rates.
Eligible patients, undergoing radiotherapy or chemoradiotherapy, are enrolled during the final week of treatment, completing questionnaires assessing nicotine dependence and alcohol use. Follow-ups are scheduled at 1, 6, and 12 months, through clinic visits or phone interviews.
The primary endpoint is the proportion of patients who remain smoke-free at 6 months. Secondary endpoints include factors influencing smoking cessation, reasons for relapse, and changes in nicotine and alcohol dependence. The study will enroll 100 patients, expecting 81 evaluable cases, with data quality ensured through regular checks and source verification.
Eligibility
Inclusion Criteria :
- Patient aged 18 years or older
- Diagnosed with head and neck cancer or lung cancer
- Undergoing curative treatment with chemoradiotherapy, radiotherapy alone, or stereotactic radiotherapy
- Current or former smoker
- Patient covered by a social security scheme
- Patient informed and having given consent for data collection
Patients with human papillomavirus (HPV) may also be included
Exclusion Criteria :
- Patient receiving palliative treatment
- Patient under guardianship or curatorship
Study Exit Criteria :
- Protocol-defined exit : After the 12-month consultation
Early exit :
- Withdrawal of consent for data collection
- Death of the patient